- Conditions
- Mild Cognitive Impairment (MCI), Early Stages of Cognitive Decline, Alzheimer's Disease Dementia, Alzheimer's Disease Diagnosis, Alzheimer's Disease and Related Dementias, Parkinson's Disease, Parkinson's Disease (PD), Parkinson's Disease With Wearing-off Motor Fluctuations, Dementia (Diagnosis), Dementia MCI (Mild Cognitive Impairment)
- Interventions
- Structured wellness care, Wearable brain-computer interface devices, Stem Cell Therapy - Experimental, Control - Placebo Comparator
- Behavioral · Device · Biological + 1 more
- Lead sponsor
- Noah Tech, Corp.
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Palisades Park, New Jersey
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Parkinson's Disease
- Interventions
- ND0612 Solution for SC infusion, Placebo for SC infusion, Oral IR-LD/CD, Placebo for Oral IR-LD/CD
- Combination Product · Drug
- Lead sponsor
- NeuroDerm Ltd.
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 381 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 38
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 34 more
- Conditions
- PARKINSON DISEASE (Disorder), Advanced Parkinson's Disease
- Interventions
- SER-252 (PEOZ-apomorphine), enFuse
- Drug · Device
- Lead sponsor
- Serina Therapeutics
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 4
- States / cities
- Englewood, Colorado • Hallandale, Florida • Maitland, Florida + 1 more
- Conditions
- Parkinson's Disease
- Interventions
- DNS-7801 (low-dose), DNS-7801 (high dose), Placebo
- Drug
- Lead sponsor
- Dart NeuroScience, LLC
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 9
- States / cities
- Long Beach, California • Pasadena, California • Englewood, Colorado + 6 more
- Conditions
- Parkinson's Disease
- Interventions
- XP21279 and carbidopa (experimental), Sinemet (comparator), Placebo for XP21279 and carbidopa, Placebo for Sinemet
- Drug
- Lead sponsor
- XenoPort, Inc.
- Industry
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Long Beach, California + 9 more
- Conditions
- Idiopathic Parkinson's Disease
- Interventions
- CVT-301, Placebo
- Drug
- Lead sponsor
- Acorda Therapeutics
- Industry
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 13
- States / cities
- Little Rock, Arkansas • Boca Raton, Florida • Port Charlotte, Florida + 10 more
- Conditions
- Parkinson's Disease
- Interventions
- rasagiline mesylate, rasagiline mesylate 1.0 mg
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 254 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 7
- States / cities
- Fresno, California • Atlanta, Georgia • Chicago, Illinois + 4 more
- Conditions
- Advanced Parkinson's Disease
- Interventions
- Levodopa-Carbidopa Intestinal Gel (LCIG), CADD-Legacy® 1400 ambulatory infusion pump, Percutaneous Endoscopic Gastrostomy with jejunal extension tube (PEG-J)
- Drug · Device
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 30 Years to 99 Years
- Enrollment
- 262 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2021
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Encinitas, California • Fountain Valley, California + 25 more
- Conditions
- Parkinson Disease
- Interventions
- CVN424 Low Dose, CVN424 High Dose, Placebo
- Drug
- Lead sponsor
- Cerevance Beta, Inc.
- Industry
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 21
- States / cities
- Long Beach, California • Pasadena, California • Boca Raton, Florida + 18 more
- Conditions
- Idiopathic Parkinson's Disease
- Interventions
- tozadenant, placebo
- Drug
- Lead sponsor
- Biotie Therapies Inc.
- Industry
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 449 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Sun City, Arizona • Loma Linda, California + 37 more
- Conditions
- Parkinson Disease
- Interventions
- Lenrispodun, Placebo
- Drug
- Lead sponsor
- Intra-Cellular Therapies, Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 35
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Irvine, California + 31 more
- Conditions
- Advanced Stage Parkinson's Disease
- Interventions
- Pardoprunox
- Drug
- Lead sponsor
- Solvay Pharmaceuticals
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 14
- States / cities
- La Jolla, California • San Francisco, California • Fort Lauderdale, Florida + 11 more
- Conditions
- Idiopathic Parkinson's Disease
- Interventions
- CVT-301 Low Dose, CVT-301 High Dose, Placebo
- Drug · Other
- Lead sponsor
- Acorda Therapeutics
- Industry
- Eligibility
- 30 Years to 85 Years
- Enrollment
- 351 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 55
- States / cities
- Scottsdale, Arizona • Fresno, California • Fullerton, California + 47 more
- Conditions
- Advanced Parkinson's Disease
- Interventions
- Levodopa carbidopa intestinal gel (LCIG), Placebo gel, Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets, Placebo (PBO) oral capsules, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube, J-tube
- Drug · Device
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Englewood, Colorado • Washington D.C., District of Columbia + 5 more
- Conditions
- Parkinson Disease
- Interventions
- Tavapadon, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 507 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 54
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Fountain Valley, California + 48 more
- Conditions
- Parkinson's Disease
- Interventions
- Sinemet 25-100 Oral Tablet, XP21279, Carbidopa Pill
- Drug
- Lead sponsor
- XenoPort, Inc.
- Industry
- Eligibility
- 30 Years to 75 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 2
- States / cities
- Peoria, Arizona • Bingham Farms, Michigan
- Conditions
- Idiopathic Parkinson's Disease
- Interventions
- Safinimide 50-100 mg/day, Matching Placebo
- Drug
- Lead sponsor
- Newron Pharmaceuticals SPA
- Industry
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 549 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 24 more
- Conditions
- Parkinson Disease
- Interventions
- ExAblate Pallidotomy, Sham ExAblate Pallidotomy
- Device
- Lead sponsor
- InSightec
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 11
- States / cities
- Stanford, California • Boynton Beach, Florida • Baltimore, Maryland + 7 more
- Conditions
- Parkinson Disease, Off Episodes
- Interventions
- APL-130277, Placebo
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 141 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 27 more
- Conditions
- Parkinson Disease
- Interventions
- IPX203
- Drug
- Lead sponsor
- Impax Laboratories, LLC
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 419 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 50
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more
- Conditions
- Parkinson's Disease
- Interventions
- VY-AADC02, Sham (Placebo) Surgery
- Biological · Other
- Lead sponsor
- Neurocrine Biosciences
- Industry
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 11
- States / cities
- Irvine, California • Sacramento, California • San Francisco, California + 8 more
- Conditions
- Parkinson's Disease With Motor Fluctuations
- Interventions
- 1 mg QD to 15 mg QD PF-06649751, 3 mg QD to 15 mg QD PF-06649751, 7 mg QD to 15 mg QD PF-06649751, 15 mg QD PF-06649751, 1 mg QD to 7 mg QD PF-06649751 (if de-escalated in parent study), 3 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study), 7 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study), 15 mg QD de-escalated to 7 mg QD PF-06649751 in parent study remain at 7 mg QD
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 40 Years to 87 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 9
- States / cities
- Newport Beach, California • Fairfield, Connecticut • Boca Raton, Florida + 5 more
- Conditions
- Parkinson's Disease (Disorder)
- Interventions
- IR CD-LD, IPX203 ER CD-LD, Placebo Matching IPX203, Placebo Matching IR CD-LD
- Drug · Other
- Lead sponsor
- Impax Laboratories, LLC
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 630 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 56
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Loma Linda, California + 46 more
- Conditions
- Parkinson's Disease
- Interventions
- 2 mg perampanel, 4 mg perampanel, placebo comparator
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 752 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 99
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Peoria, Arizona + 82 more